Diker Management’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-429
Closed -$7K 37
2019
Q3
$7K Hold
429
﹤0.01% 32
2019
Q2
$10K Hold
429
﹤0.01% 34
2019
Q1
$15K Hold
429
0.01% 37
2018
Q4
$16K Hold
429
0.01% 52
2018
Q3
$67K Hold
429
0.02% 53
2018
Q2
$57K Hold
429
0.02% 51
2018
Q1
$106K Sell
429
-18
-4% -$5.07K 0.04% 56
2017
Q4
$124K Hold
447
0.04% 60
2017
Q3
$181K Buy
447
+12
+3% +$6.26K 0.07% 56
2017
Q2
$258K Buy
435
+13
+3% +$7.6K 0.11% 52
2017
Q1
$260K Buy
422
+177
+72% +$63K 0.12% 53
2016
Q4
$50K Buy
245
+46
+23% +$10.5K 0.02% 60
2016
Q3
$52K Hold
199
0.02% 62
2016
Q2
$59K Hold
199
0.02% 61
2016
Q1
$85K Buy
199
+7
+4% +$2.62K 0.03% 55
2015
Q4
$95K Hold
192
0.03% 77
2015
Q3
$225K Hold
192
0.05% 99
2015
Q2
$339K Buy
192
+39
+25% +$60.6K 0.06% 109
2015
Q1
$180K Sell
153
-80
-34% -$94.7K 0.03% 114
2014
Q4
$234K Buy
233
+33
+17% +$33.1K 0.05% 94
2014
Q3
$270K Buy
200
+18
+10% +$25.8K 0.05% 88
2014
Q2
$308K Buy
182
+36
+25% +$68.5K 0.07% 87
2014
Q1
$331K Buy
146
+69
+90% +$177K 0.07% 88
2013
Q4
$158K Buy
+77
New +$166K 0.04% 90

Other funds holding VYNT

Diker Management's VYNT Position: Q4 2019 in Review

Diker Management sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2019, closing a stake of 429 shares — an estimated $7K sold.

Diker Management first reported a position in VYNT in Q4 2013 and held it in 24 quarters. The position peaked at $339K in Q2 2015. 18 funds tracked by Wall St. Rank hold VYNT as of Q4 2019.

  • Diker Management reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Diker Management sold 429 Vyant Bio, Inc. Common Stock shares in Q4 2019, an estimated $7K.
  • Diker Management first reported a position in Vyant Bio, Inc. Common Stock in Q4 2013 and held it in 24 quarters.
  • Diker Management's Vyant Bio, Inc. Common Stock position peaked at $339K in Q2 2015.
  • 18 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2019.

Based on Diker Management's 13F filing for Q4 2019, filed 14 Feb 2020.